Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | GRM5 | P41594 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29052706 | 1.00 | ADORA1 (0.45) | ADORA1GRM5SMN1; SMN2RECQLHPGD | |
| SCHEMBL5379778 | 1.00 | ADORA1 (0.45) | ADORA1GRM5SMN1; SMN2RECQLHPGD | |
| SCHEMBL803581 | 0.95 | ADORA1 (0.48) | ADORA1GRM5SMN1; SMN2RECQLUSP2 | |
| SCHEMBL4710869 | 0.90 | ADORA1 (0.45) | ADORA1GRM5SMN1; SMN2RECQLHPGD | |
| SCHEMBL4710868 | 0.90 | ADORA1 (0.45) | ADORA1GRM5SMN1; SMN2RECQLHPGD | |
| SCHEMBL4710867 | 0.90 | ADORA1 (0.45) | ADORA1GRM5SMN1; SMN2RECQLHPGD | |
| SCHEMBL22679830 | 0.87 | ADORA1 (0.52) | ADORA1GRM5SMN1; SMN2RECQLUSP2 | |
| SCHEMBL1900963 | 0.87 | ADORA1 (0.52) | ADORA1GRM5SMN1; SMN2RECQLUSP2 | |
| SCHEMBL2355722 | 0.87 | ADORA1 (0.52) | ADORA1GRM5SMN1; SMN2RECQLUSP2 | |
| SCHEMBL30793314 | 0.86 | ADORA1 (0.44) | ADORA1GRM5SMN1; SMN2RECQLHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116600813-A | Phosphonates as ENPP1 and CDNP inhibitors | 斯汀格瑞治疗股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7164024-B2 | Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20040147506-A1 | Benzimidazolone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147506-A1 | Benzimidazolone derivatives | HRH2, CCKAR, HRH4 | ADORA1 303/4885GRM5 608/4885SMN1; SMN2 1070/4885 |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | ADORA1 2687/4885GRM5 2068/4885SMN1; SMN2 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.